Sarissa Capital Management LP Long-Term Concentrated

Location: Greenwich, CT

CIK: 0001577524 · Show all filings

Period: Q1 2017 (← Previous) (Next →)

Filing Date: May 15, 2017

Total Value: $253M (100.0% shares, 0.0% debt)

Holdings (11)

— MEDICINES CO 33.9%

Value $85.67M Shares 1,752,000 Est. Cost $29.63 Unrealized —

BIIB BIOGEN INC 33.5%

Value $84.76M Shares 310,000 Est. Cost $287.35 Unrealized -1.6%

INVA INNOVIVA INC 18.7%

Value $47.37M Shares 3,425,000 Est. Cost $11.01 Unrealized +7.0%

— NOVELION THERAPEUTICS INC 4.4%

Value $11.01M Shares 1,025,000 Est. Cost $8.42 Unrealized —

— BIOVERATIV INC 3.3%

Value $8.441M Shares 155,000 Est. Cost $54.46 Unrealized —

— INTRA CELLULAR THERAPIES INC 2.3%

Value $5.85M Shares 360,000 Est. Cost $27.96 Unrealized —

— APRICUS BIOSCIENCES INC 1.2%

Value $3.055M Shares 1,447,906 Est. Cost $1.30 Unrealized —

— VIVUS INC 1.1%

Value $2.882M Shares 2,573,943 Est. Cost $9.08 Unrealized —

— ADVAXIS INC 1.1%

Value $2.771M Shares 339,180 Est. Cost $8.09 Unrealized —

ABBV ABBVIE INC. 0.3%

Value $651K Shares 10,000 Est. Cost $38.85 Unrealized +11.9%

— AVEO PHARMACEUTICALS INC 0.2%

Value $598K Shares 1,013,616 Est. Cost $1.84 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	MEDICINES CO	1,752,000	$85.67M	33.9%	$29.63	—	COM	584688105
BIIB	BIOGEN INC	310,000	$84.76M	33.5%	$287.35	-1.6%	COM	09062X103
INVA	INNOVIVA INC	3,425,000	$47.37M	18.7%	$11.01	+7.0%	COM	45781M101
—	NOVELION THERAPEUTICS INC	1,025,000	$11.01M	4.4%	$8.42	—	COM NEW	67001K202
—	BIOVERATIV INC	155,000	$8.441M	3.3%	$54.46	—	COM	09075E100
—	INTRA CELLULAR THERAPIES INC	360,000	$5.85M	2.3%	$27.96	—	COM	46116X101
—	APRICUS BIOSCIENCES INC	1,447,906	$3.055M	1.2%	$1.30	—	COM NEW	03832V307
—	VIVUS INC	2,573,943	$2.882M	1.1%	$9.08	—	COM	928551100
—	ADVAXIS INC	339,180	$2.771M	1.1%	$8.09	—	COM NEW	007624208
ABBV	ABBVIE INC.	10,000	$651K	0.3%	$38.85	+11.9%	COM	00287Y109
—	AVEO PHARMACEUTICALS INC	1,013,616	$598K	0.2%	$1.84	—	COM	053588109